Since the first trans-aortic valve replacement (TAVR) in 2002 1
, the field of TAVR has rapidly evolved, with major refinements in technology, procedural techniques and patient selection. TAVR was first used in inoperable and high-risk patients with symptomatic aortic stenosis (AS) after the results of PARTNER 1 trials 2 . Then the SURTAVI and PARTNER 2 studies assessed the non-inferiority of TAVR when compared to SAVR in intermediate risk patients with severe, symptomatic AS 4 . The PARTNER 3 studies published in march 2019 eventually assessed the non-inferiority of the percutaneous approach with...Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com